# Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

> **NCT04233918** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Evinacumab

## Key facts

- **NCT ID:** NCT04233918
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-29
- **Primary completion:** 2022-01-31
- **Final completion:** 2023-05-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233918, "Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04233918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*